Spectrum Pharmaceuticals Inc. (SPPI)

11.58
0.00 (0.00)
NASDAQ : Health Technology
Prev Close 11.58
Open 11.47
Day Low/High 11.37 / 11.87
52 Wk Low/High 11.38 / 25.29
Volume 879.31K
Avg Volume 1.37M
Exchange NASDAQ
Shares Outstanding 104.06M
Market Cap 1.32B
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
Spectrum Pharmaceuticals Announces Results From The RECOVER Phase 3 Study Of ROLONTIS® (eflapegrastim) At The 2018 SABCS Annual Meeting

Spectrum Pharmaceuticals Announces Results From The RECOVER Phase 3 Study Of ROLONTIS® (eflapegrastim) At The 2018 SABCS Annual Meeting

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that data from the Phase 3 RECOVER clinical study...

Spectrum Pharmaceuticals Announces Positive Results From Phase 2 Trial Evaluating Use Of Oral Leucovorin To Potentially Mitigate Mucositis In Patients Treated With FOLOTYN® (pralatrexate)

Spectrum Pharmaceuticals Announces Positive Results From Phase 2 Trial Evaluating Use Of Oral Leucovorin To Potentially Mitigate Mucositis In Patients Treated With FOLOTYN® (pralatrexate)

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced results from a prospective Phase 2 single-arm,...

Spectrum Pharmaceuticals Highlights Three Posters At The 60th Annual Meeting Of The American Society Of Hematology

Spectrum Pharmaceuticals Highlights Three Posters At The 60th Annual Meeting Of The American Society Of Hematology

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced presentations of clinical and scientific data related to...

Spectrum Pharmaceuticals Appoints Dr. Jeffrey Vacirca To Its Board Of Directors

Spectrum Pharmaceuticals Appoints Dr. Jeffrey Vacirca To Its Board Of Directors

Spectrum Pharmaceuticals Inc., (NASDAQ: SPPI) a biotechnology company with fully integrated commercial and drug development operations and a primary focus in hematology and oncology, today announced the appointment of Jeffrey Vacirca, MD, FACP to its...

Spectrum Pharmaceuticals Reports Third Quarter 2018 Pipeline Update And Financial Results

Spectrum Pharmaceuticals Reports Third Quarter 2018 Pipeline Update And Financial Results

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today financial results for the three-month period ended...

Spectrum Pharmaceuticals To Present Corporate Update At The Jefferies 2018 London Healthcare Conference On November 14

Spectrum Pharmaceuticals To Present Corporate Update At The Jefferies 2018 London Healthcare Conference On November 14

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy and...

Spectrum Pharmaceuticals Announces Third Quarter 2018 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals Announces Third Quarter 2018 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management...

Running Hot: Cramer's 'Mad Money' Recap (Friday 10/5/18)

Running Hot: Cramer's 'Mad Money' Recap (Friday 10/5/18)

Jim Cramer says it'll be hard for stocks to stabilize until the Fed's stance softens. He's got your game plan for next week.

Camping World, American Electric Power: 'Mad Money' Lightning Round

Camping World, American Electric Power: 'Mad Money' Lightning Round

Jim Cramer takes a look at Camping World, American Electric Power, Avangrid, Dominion Energy, Thor Industries, Spectrum Pharmaceuticals and more.

Spectrum Pharmaceuticals Receives FDA Approval Of KHAPZORY™ (levoleucovorin) For Injection

Spectrum Pharmaceuticals Receives FDA Approval Of KHAPZORY™ (levoleucovorin) For Injection

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the U.

Spectrum Pharmaceuticals Announces Dr. Francois Lebel As Chief Medical Officer

Spectrum Pharmaceuticals Announces Dr. Francois Lebel As Chief Medical Officer

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the appointment of Francois Lebel, M.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: MTR Downgrades: ELLI, GRPN, SPPI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Spectrum Pharmaceuticals To Present Corporate Update At The 2018 Cantor Global Healthcare Conference On October 2

Spectrum Pharmaceuticals To Present Corporate Update At The 2018 Cantor Global Healthcare Conference On October 2

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy and...

Spectrum Pharmaceuticals Announces Release Of Updated Poziotinib Data From MD Anderson Phase 2 Study In Non-Small Cell Lung Cancer Patients

Spectrum Pharmaceuticals Announces Release Of Updated Poziotinib Data From MD Anderson Phase 2 Study In Non-Small Cell Lung Cancer Patients

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced preliminary poziotinib data from the University of...

Spectrum Pharmaceuticals Expands Poziotinib Clinical Trial Into First-Line Therapy And Doses First Patient

Spectrum Pharmaceuticals Expands Poziotinib Clinical Trial Into First-Line Therapy And Doses First Patient

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that it has initiated two new cohorts for...

Spectrum Pharmaceuticals Announces Release Of Poziotinib Abstract As Part Of The IASLC 19th World Conference On Lung Cancer

Spectrum Pharmaceuticals Announces Release Of Poziotinib Abstract As Part Of The IASLC 19th World Conference On Lung Cancer

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced new interim poziotinib data from the MD Anderson...

Spectrum Pharmaceuticals To Present At Two Upcoming Investor Conferences In September

Spectrum Pharmaceuticals To Present At Two Upcoming Investor Conferences In September

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AGN, DSS, ENDP, ICUI, PIH, SPB, SPPI, WAAS, YRD Downgrades: BMA, BRT, ELSE, FRBK, HAE, HSKA, JD, MATW, TCMD, TSG Initiations: ALT, TRTX Read on to get TheStreet Quant Ratings' detailed report:

Spectrum Pharmaceuticals Reports Second Quarter 2018 Financial Results And Pipeline Update

Spectrum Pharmaceuticals Reports Second Quarter 2018 Financial Results And Pipeline Update

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today financial results for the three-month period ended...

Spectrum Pharmaceuticals Announces Second Quarter 2018 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals Announces Second Quarter 2018 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management...

Spectrum Pharmaceuticals Presents ADVANCE Phase 3 ROLONTIS® (eflapegrastim) Data At MASCC 2018 And Announces The Phase 3 RECOVER Study Met The Primary Endpoint

Spectrum Pharmaceuticals Presents ADVANCE Phase 3 ROLONTIS® (eflapegrastim) Data At MASCC 2018 And Announces The Phase 3 RECOVER Study Met The Primary Endpoint

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced detailed data from the ADVANCE Phase 3 study which...

Spectrum Pharmaceuticals To Host Conference Call Highlighting ROLONTIS® (eflapegrastim) Phase 3 ADVANCE Study Data Presented At Multinational Association Of Supportive Care in Cancer (MASCC)

Spectrum Pharmaceuticals To Host Conference Call Highlighting ROLONTIS® (eflapegrastim) Phase 3 ADVANCE Study Data Presented At Multinational Association Of Supportive Care in Cancer (MASCC)

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the company will hold a conference call on Friday, June 29...

CORRECTING And REPLACING Spectrum Pharmaceuticals Announces Detailed Results From Phase 3 Study Of ROLONTIS® (eflapegrastim) Published In An ASCO Abstract

CORRECTING And REPLACING Spectrum Pharmaceuticals Announces Detailed Results From Phase 3 Study Of ROLONTIS® (eflapegrastim) Published In An ASCO Abstract

Fourth paragraph, first sentence of release dated May 16, 2018, should read: "The ADVANCE study is a cornerstone in the ROLONTIS clinical program, which includes one Phase 2 and two Phase 3 clinical studies involving approximately 800 patients" (instead...

Spectrum Pharmaceuticals To Present Corporate Update At The Bank Of America Merrill Lynch 2018 Health Care Conference On May 16th

Spectrum Pharmaceuticals To Present Corporate Update At The Bank Of America Merrill Lynch 2018 Health Care Conference On May 16th

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy and...

Spectrum Pharmaceuticals Reports First Quarter 2018 Financial Results And Pipeline Update

Spectrum Pharmaceuticals Reports First Quarter 2018 Financial Results And Pipeline Update

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today financial results for the three-month period ended...

Spectrum Pharmaceuticals Announces Exclusive Licensing Agreement On Certain Methods Of Use Of Poziotinib With The University Of Texas MD Anderson Cancer Center

Spectrum Pharmaceuticals Announces Exclusive Licensing Agreement On Certain Methods Of Use Of Poziotinib With The University Of Texas MD Anderson Cancer Center

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today an exclusive licensing agreement with The University...

Spectrum Pharmaceuticals Enters Into A Next-Generation Sequencing Companion Diagnostic Partnership With Thermo Fisher Scientific

Spectrum Pharmaceuticals Enters Into A Next-Generation Sequencing Companion Diagnostic Partnership With Thermo Fisher Scientific

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it has entered into an agreement with Thermo Fisher...

Spectrum Pharmaceuticals Announces Corporate Governance Enhancements And Board Changes

Spectrum Pharmaceuticals Announces Corporate Governance Enhancements And Board Changes

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today that it has taken a number of actions designed to...

Company Profile For SPECTRUM PHARMACEUTICALS

Company Profile For SPECTRUM PHARMACEUTICALS

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology.

TheStreet Quant Rating: D (Sell)